Dr. Kumar Discusses Advances in the Field of Multiple Myeloma

Shaji K. Kumar, MD
Published: Wednesday, Jun 28, 2017



Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses advances in the field of multiple myeloma.

The field of multiple myeloma, especially in the newly diagnosed patients, is moving forward, says Kumar.

The first completely oral treatment for newly diagnosed patients with multiple myeloma is ixazomib (Ninlaro), lenalidomide (Revlimid) and dexamethasone, which is under investigation now.
 


Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses advances in the field of multiple myeloma.

The field of multiple myeloma, especially in the newly diagnosed patients, is moving forward, says Kumar.

The first completely oral treatment for newly diagnosed patients with multiple myeloma is ixazomib (Ninlaro), lenalidomide (Revlimid) and dexamethasone, which is under investigation now.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x